Piribo: Abbott Laboratories, new publication announcement

Abbott is active in the areas of pharmaceuticals, nutritionals, hospital products and diagnostics. Within pharmaceuticals Abbott focuses on several therapeutic areas including diabetes, pain management, respiratory infections, HIV/AIDS, men and women's health, paediatrics and animal health. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Abbott researches, develops, manufactures and sells a broad and diversified line of healthcare products and services, comprising mainly prescription pharmaceuticals, nutritionals, hospital pharmaceuticals and diagnostics, in more than 130 countries. A major component of Abbott's operations is its 50:50 joint venture with Takeda, TAP Pharmceuticals, which mainly markets prescription pharmaceuticals in Japan.

Abbott markets pharmaceuticals in the following therapeutic areas: Immunology and Inflammation; Neuroscience and Pain Care; Anti-infectives; Virology; Cardiovascular; Metabolics; Gastrointestinal and Oncology. The company's research and development efforts are principally focused on Immunology and Inflammation, Neuroscience and Pain Care, Virology, Metabolics and Oncology.

Current Growth Drivers
Humira (D2E7; adalimumab) is a fully-human monoclonal antibody designed to specifically block the activity of TNF alpha. In 2005, Humira became Abbott's top selling product and achieved launches in the US and Europe for the new indications of psoriatic arthritis and early rheumatoid arthritis.

Kaletra (lopinavir+ritonavir) is a combination of two antiretroviral protease inhibitors (ARV PIs) for the treatment of HIV infection in adults and children aged six months and over, in combination with other ARV medications. In 2005, two new formulations of Kaltera were approved and launched in US: a once-daily dosing regimen for both liquid and soft gel capsules; and a new tablet formulation to be used in combination with other ARV medications.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents
Executive Summary
Product Portfolio/Research & Development
Appendix 1 - Financial Performance
Appendix 2 - Key Agreements
Appendix 3 - Infrastructure
Appendix 4 - Key Pharmaceutical

“Abbott Laboratories - Prospects to 2010” is available from Piribo. For more information go to: http://www.piribo.com/publications/pharmaceutical_companies/abbott_laboratories/abbott_laboratories.html

Piribo Product ID: ESP958

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.